Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib

Janeway, Katherine A., Albritton, Karen H., Van Den Abbeele, Annick D., D'Amato, Gina Z., Pedrazzoli, Paolo, Siena, Salvatore, Picus, Joel, Butrynski, James E., Schlemmer, Marcus, Heinrich, Michael C., Demetri, George D. · 2009 · Pediatric Blood & Cancer

Abstract

Background: Sunitinib inhibits KIT and other members of the split‐kinase‐domain family of receptor tyrosine kinases. Sunitinib prolongs survival in adult patients with imatinib‐resistant gastrointestinal stromal tumor (GIST). We report the experience with sunitinib in pediatric patients with advanced GIST following failure of imatinib. Procedure: Sunitinib therapy was provided through a treatment‐use protocol. Patients were 10–17 years old at enrollment. All patients had GIST resistant to imatinib therapy. Sunitinib was administered daily for 4 weeks in 6‐week treatment cycles. KIT and platelet‐derived growth factor receptor alpha (PDGFRA) genotyping of tumor tissue were performed. Results: One patient achieved a partial response, five patients had stable disease and one patient had progressive disease on sunitinib. The duration of disease stabilization was between 7 and 21+ months, with a mean of 15 months. Time to tumor progression was longer on sunitinib than on prior imatinib treatment for five of six patients. Two patients experienced grade 3 adverse events. All other adverse events were grade 1–2. None of the five patients tested had mutations in KIT or PDGFRA. Conclusion: Sunitinib treatment was associated with substantial initial antitumor activity and acceptable tolerability in this group of pediatric patients with imatinib‐resistant GIST. Pediatr Blood Cancer 2009;52:767–771. © 2009 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pbc.21909

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

Metadata

Authors
Janeway, K. A., Albritton, K. H., Van Den Abbeele, A. D., D'Amato, G. Z., Pedrazzoli, P., Siena, S., Picus, J., Butrynski, J. E., Schlemmer, M., Heinrich, M. C., & Demetri, G. D.
Venue
Pediatric Blood & Cancer
Publisher
Wiley
Published
2009-03-26
Volume
52
Issue
7
Pages
767-771
ISSN
  • 1545-5009 (ISSN-L)
  • 1545-5017
OpenAlex
W1975011523
Cited by
162
References
1
FWCI
14.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.